Biotech Stock News (ARWR) (GILD) (HRTX) (VRTX)

Arrowhead Research (NASDAQ:ARWR) On September 24, 2015 shares of Arrowhead were up as much as 20% after announcing positive phase 2a trial results for its Hepatitis B trial. Investors thought the results were good which is why the stock ended the day on the positive side. In addition to obtaining positive phase 2a Hep B … Read more

Gilead Sciences (GILD) Recovers In A Big Way

Gilead Sciences, In. (NASDAQ: GILD) Gilead Sciences stock is having an incredible day in the market. As I predicted yesterday, the stock is making a full recovering and “coming back roaring”. As a matter of fact, thanks to the gains we’ve seen this morning, Gilead Sciences has completely recovered from the two day losses we … Read more

Gilead Sciences (GILD) Stock Will Come Back Roaring

Gilead Sciences, Inc. (NASDAQ: GILD) The US market has had a rough time over recent days; there’s absolutely no denying that. There’s also no denying the fact that Gilead Sciences experienced downward trends along with the rest of the market. However, if there’s one stock that I have faith in with regard to a strong … Read more

Gilead Sciences (GILD) Continues To Climb, Can It Last?

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences is what I believe to be one of the most under-appreciated stocks in the biotech space. However, I think that’s likely to change quickly. Earlier this week, the company released its earnings report; proving to produce better results than analysts and investors expected and climbing in the market. … Read more

Gilead Sciences Climbs On Positive Earnings

Gilead Sciences, Inc. (NASDAQ: GILD) As expected, Gilead Sciences reported their earnings for the second quarter after the closing bell on Tuesday; and as I predicted earlier this week, the report was overwhelmingly positive. Today, we’ll take a look at Gilead’s earnings for the second quarter, how investors reacted, and what we can expect to … Read more

Top 5 Analysts to Watch Ahead of Gilead Sciences, Inc’s (GILD) Earnings

By Sarah Roden Gilead Sciences, Inc. (NASDAQ:GILD) will release second quarter earnings on Tuesday, July 28 after the bell. The biopharmaceutical giant is most known for its hepatitis C drugs, Harvoni and Sovaldi. Several analysts weighed in on Gilead after the company posted a strong earnings report in May. Here are the top 5 analysts … Read more